Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate e...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cia2.12302 |
| _version_ | 1827159204341743616 |
|---|---|
| author | Makoto Ito Masahiro Kamata Hideaki Uchida Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Takeko Ishikawa Yayoi Tada |
| author_facet | Makoto Ito Masahiro Kamata Hideaki Uchida Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Takeko Ishikawa Yayoi Tada |
| author_sort | Makoto Ito |
| collection | DOAJ |
| description | Abstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate exacerbation of AD after switching from upadacitinib to dupilumab, and herein report these cases. This phenomenon is attributed to the difference in elimination half‐life of the two drugs and a slower onset of efficacy of dupilumab than upadacitinib. When switching from a JAK inhibitor to dupilumab, short‐term concomitant use, intensifying topical treatment, and/or rescue with cyclosporine should be considered. |
| first_indexed | 2024-03-08T06:50:57Z |
| format | Article |
| id | doaj.art-4b139843692745c887fbbfb2d450e943 |
| institution | Directory Open Access Journal |
| issn | 2574-4593 |
| language | English |
| last_indexed | 2025-03-20T23:53:25Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Cutaneous Immunology and Allergy |
| spelling | doaj.art-4b139843692745c887fbbfb2d450e9432024-08-03T12:00:44ZengFrontiers Media S.A.Journal of Cutaneous Immunology and Allergy2574-45932023-10-016516817110.1002/cia2.12302Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two casesMakoto Ito0Masahiro Kamata1Hideaki Uchida2Shota Egawa3Saki Fukaya4Kotaro Hayashi5Atsuko Fukuyasu6Takamitsu Tanaka7Takeko Ishikawa8Yayoi Tada9Department of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanDepartment of Dermatology Teikyo University School of Medicine Tokyo JapanAbstract Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate exacerbation of AD after switching from upadacitinib to dupilumab, and herein report these cases. This phenomenon is attributed to the difference in elimination half‐life of the two drugs and a slower onset of efficacy of dupilumab than upadacitinib. When switching from a JAK inhibitor to dupilumab, short‐term concomitant use, intensifying topical treatment, and/or rescue with cyclosporine should be considered.https://doi.org/10.1002/cia2.12302atopic dermatitisbiologicsdupilumabJanus kinaseupadacitinib |
| spellingShingle | Makoto Ito Masahiro Kamata Hideaki Uchida Shota Egawa Saki Fukaya Kotaro Hayashi Atsuko Fukuyasu Takamitsu Tanaka Takeko Ishikawa Yayoi Tada Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases Journal of Cutaneous Immunology and Allergy atopic dermatitis biologics dupilumab Janus kinase upadacitinib |
| title | Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases |
| title_full | Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases |
| title_fullStr | Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases |
| title_full_unstemmed | Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases |
| title_short | Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases |
| title_sort | immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab a report of two cases |
| topic | atopic dermatitis biologics dupilumab Janus kinase upadacitinib |
| url | https://doi.org/10.1002/cia2.12302 |
| work_keys_str_mv | AT makotoito immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT masahirokamata immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT hideakiuchida immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT shotaegawa immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT sakifukaya immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT kotarohayashi immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT atsukofukuyasu immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT takamitsutanaka immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT takekoishikawa immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases AT yayoitada immediateexacerbationofatopicdermatitisafterswitchingfromupadacitinibtodupilumabareportoftwocases |